All In Biotech

Drug Trial Radar · NCT01675297

Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis

For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Aug 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,053 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,053

Actual

Start

Jul 4, 2011

Primary completion

Dec 2013

Study completion Apr 15, 2014

Sponsor

Lead sponsor
Hanlim Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 29, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis.

Conditions

  • Osteoporosis

Interventions

  • Risedronate/Cholecalciferol combinationDrug

    Risendronate/Cholecalciferol combination once a week

  • RisedronateDrug

    Risedronate once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change of Bone Mineral Density (BMD) ValueTime frame: baseline and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chung-ang university hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.